2017 News Releases
Filter News by: 2017 | 2016 | 2015
 
05/17/17CytRx to Present Global Phase 3 Aldoxorubicin Clinical Data in Patients with Soft Tissue Sarcomas at the 2017 American Society of Clinical Oncology Annual MeetingPrinter Friendly Version
05/10/17CytRx Reports First Quarter 2017 Financial ResultsPrinter Friendly Version
04/28/17CytRx Corporation Announces Pricing of $15 Million Public Offering of Common StockPrinter Friendly Version
04/27/17CytRx Corporation Announces Proposed Public Offering of Common StockPrinter Friendly Version
04/21/17CytRx to Present Aldoxorubicin Clinical Trial Data in Patients with Soft Tissue Sarcomas at the 2017 American Society of Clinical Oncology Annual Meeting (ASCO)Printer Friendly Version
04/19/17CytRx Announces FDA Agreement on Regulatory Pathway to Approval for Aldoxorubicin in Soft Tissue SarcomasPrinter Friendly Version
03/15/17CytRx Reports 2016 Financial ResultsPrinter Friendly Version
03/07/17CytRx to Present at the 29th Annual ROTH ConferencePrinter Friendly Version
02/06/17CytRx to Present at the 19th Annual BIO CEO & Investor ConferencePrinter Friendly Version
01/04/17CytRx Granted Type B Pre-NDA Meeting with U.S. FDA for Registration Pathway with Aldoxorubicin as a Treatment for Patients with Relapsed Soft Tissue SarcomasPrinter Friendly Version